cell engager, immune-oncology therapeutics, immuno-oncology, IO therapeutics, T-cell
0 Comment
Learn from the pioneers of immunotherapy
cancer, CAR T, cell therapy, Oncology, T-cell
0 Comment
Engineering Smarter Adoptive Cell Therapies
immunogenic, infectious disease, SARS-CoV-2, T-cell, vaccine
0 Comment
Cell-Mediated Therapies for Infectious Disease Summit
solid tumors, T-cell, target selection, TCR, tumor microenvironment
0 Comment
Development of next-generation TCR-T products
Adaptimmune, cancer, immuno-oncology, Juno, Kite, T-cell
0 Comment
T-cell trial will include controversial chemo agent fludarabine.
Adaptimmune, cancer, synovial sarcoma, T-cell
0 Comment
Biotech says “robust” clinical response in early stage trial.
4-1BB, cancer, immuno-oncology, immunotherapy, Keytruda, Oncology, Opdivo, PD-1, R&D, T-cell
0 Comment
As immuno-oncology increasingly involves more than one agent for best efficacy, market positioning must take a pan-tumour approach.
Adaptimmune, cancer, GlaxoSmithKline, T-cell
0 Comment
Regulator asks for information on trial design.
